Biohaven won’t face FDA advisory committee meeting for its SCA drug

Biohaven won’t need to go before an FDA advisory committee to discuss its spinocerebellar ataxia drug, the company said Friday. According to Biohaven, the FDA "determined that an advisory committee meeting is no longer needed ...